Paul Rennie
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
Paul Rennie
Founder, Chair / Paradigm Biopharmaceuticals
Paul Rennie has sales, marketing, business development, operational and IP commercialisation experience in the biopharmaceutical sector.
His experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as national sales and marketing manager, and as director of business development at Soltec (FH Faulding).
Mr Rennie also led the commercialisation of Recaldent, a novel biopharmaceutical arising from research at the dental school, University of Melbourne.
He has worked in a number of positions with Mesoblast, and was the inaugural chief operating officer and executive vice president of new product development for the adult stem cell company.
His experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as national sales and marketing manager, and as director of business development at Soltec (FH Faulding).
Mr Rennie also led the commercialisation of Recaldent, a novel biopharmaceutical arising from research at the dental school, University of Melbourne.
He has worked in a number of positions with Mesoblast, and was the inaugural chief operating officer and executive vice president of new product development for the adult stem cell company.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 10th | Arovella Therapeutics | 432% | 110% |
| 39th | Biotron | 184% | 1% |
| 1767th | Spark Infrastructure Group | -72% | -22% |
| 1780th | Paradigm Biopharmaceuticals | -73% | -20% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 832nd |  | Paradigm Biopharmaceuticals | $6.8m |
| 974th | | Arovella Therapeutics | $1.5m |
| 975th | | Biotron | $1.4m |
| 977th | | Spark Infrastructure Group | $1.4m |
| 978th | | Argonaut Resources NL | $1.4m |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEWS: Tagged in Board Moves December 5, 2023 | 05 Dec 2023 |
| NEWS: Tagged in Board Moves August 31, 2023 | 31 Aug 2023 |
| NEWS: Tagged in NeuroScientific boss resigns after trial fail | 09 Sep 2022 |
| NEW ROLE: Non-Executive Chair, NeuroScientific Biopharmaceuticals | 22 Jun 2021 |
| NEW ROLE: Founder, Chair, Paradigm Biopharmaceuticals | 03 Nov 2020 |
